These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 15076168)

  • 21. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.
    Spindler SR; Mote PL; Flegal JM
    Age (Dordr); 2016 Dec; 38(5-6):379-391. PubMed ID: 27590905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.
    Mukawa H; Toki Y; Miyazaki Y; Matsui H; Okumura K; Ito T
    Hypertens Res; 2003 Jan; 26(1):89-95. PubMed ID: 12661917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
    Pollock DM; Morsing P
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients.
    Rostoker G; Griuncelli M; Benmaadi A
    Ren Fail; 2006; 28(4):283-6. PubMed ID: 16771242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats.
    Wada T; Sanada T; Ojima M; Kanagawa R; Nishikawa K; Inada Y
    Hypertens Res; 1996 Dec; 19(4):247-54. PubMed ID: 8986455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of AT1 receptor antagonist and spironolactone on cardiac expression of ET-1 mRNA in SHR-SP/Izm.
    Naruse M; Tanabe A; Hara Y; Takagi S; Imaki T; Takano K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S1-3. PubMed ID: 15838251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.
    Wang Z; Niu Q; Peng X; Li M; Liu K; Liu Y; Liu J; Jin F; Li X; Wei Y
    Int J Cardiol; 2016 Jul; 214():348-57. PubMed ID: 27085127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q; Larouche I; Schiffrin EL
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D; George M; Hübner R; Olofsson B
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
    Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
    J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ; Goa KL
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
    Zorad S; Dou JT; Benicky J; Hutanu D; Tybitanclova K; Zhou J; Saavedra JM
    Eur J Pharmacol; 2006 Dec; 552(1-3):112-22. PubMed ID: 17064684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
    Gohlke P; Linz W; Schölkens B; Van Even P; Martorana P; Unger T
    Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.